WO2001012167A2 - Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist - Google Patents

Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist Download PDF

Info

Publication number
WO2001012167A2
WO2001012167A2 PCT/GB2000/003118 GB0003118W WO0112167A2 WO 2001012167 A2 WO2001012167 A2 WO 2001012167A2 GB 0003118 W GB0003118 W GB 0003118W WO 0112167 A2 WO0112167 A2 WO 0112167A2
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
hydroxy
ethyl
phenylethoxy
benzothiazol
Prior art date
Application number
PCT/GB2000/003118
Other languages
French (fr)
Other versions
WO2001012167A3 (en
Inventor
Francis Ince
John Dixon
Philip Ronald Holt
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Priority to AU64604/00A priority Critical patent/AU6460400A/en
Publication of WO2001012167A2 publication Critical patent/WO2001012167A2/en
Publication of WO2001012167A3 publication Critical patent/WO2001012167A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine

Definitions

  • the present invention relates to combinations of pharmaceutically active substances for use in the treatment of obstructive airways diseases.
  • a pharmaceutical composition comprising, in admixture, a first active ingredient (A) being 4-hydroxy-7-[2- [2-[3-[2-phenylethoxy]propylsulphonyllethylamino]ethyl]- 1 ,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, and a second active ingredient (B) being an anticholinergic muscarinic antagonist.
  • the invention also provides a pharmaceutical product comprising, in combination, a preparation of a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]- propylsulphonyl]ethylamino]ethyl]-l,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, and a preparation of a second active ingredient (B) being an anticholinergic muscarinic antagonist for sequential or separate use in therapy.
  • A a preparation of a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]- propylsulphonyl]ethylamino]ethyl]-l,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, and a preparation of a second active ingredient (B) being an anticholinergic muscarinic antagonist for sequential or separate use in therapy.
  • B an anticholinergic muscar
  • the invention provides a kit comprising a preparation of a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]- ethylamino]ethyl]- 1 ,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, a preparation of a second active ingredient (B) being an anticholinergic muscarinic antagonist, and instructions for the sequential or separate administration of the preparations to a patient in need thereof.
  • A being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]- ethylamino]ethyl]- 1 ,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof
  • B an anticholinergic muscarinic antagonist
  • the combination of active ingredients according to the invention is advantageous because it is beneficial in the treatment of obstructive airways diseases including chronic obstructive pulmonary disease (COPD); and asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness).
  • COPD chronic obstructive pulmonary disease
  • asthma such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness).
  • COPD chronic obstructive pulmonary disease
  • asthma such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness).
  • the active ingredient (A) is most preferably 4-hydroxy-7-[2-[2-[3-[2- phenylethoxy]propylsulphonyl]ethylamino]ethyl]-l,3-benzothiazol-2(3H)-one hydrochloride.
  • Examples of the active ingredient (B) having anticholinergic activity include the muscarinic antagonists:
  • the pharmaceutical composition of the invention may be prepared by mixing the first active ingredient (A) with the second active ingredient (B). Therefore, in another aspect of the present invention, there is provided a process for the preparation of a pharmaceutical composition which comprises mixing a first active ingredient (A) being 4-hydroxy-7-[2-[2- [3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]- 1 ,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, with a second active ingredient (B) being an anticholinergic muscarinic antagonist.
  • the pharmaceutical composition of the invention will typically comprise a total amount of first active ingredient (A) and second active ingredient (B) in the range from 0.05 to 99 %w (per cent by weight), more preferably in the range from 0.10 to 70 %w, and even more preferably in the range from 0.10 to 50 %w, all percentages by weight being based on total composition.
  • the first and second active ingredients (A) and (B) may alternatively be administered sequentially or separately in any suitable order to treat obstructive airways diseases.
  • sequential is meant that the first and second active ingredients are administered one immediately after the other. They still have the desired effect if they are administered separately but less than about 4 hours apart, preferably less than about 2 hours apart, more preferably less than about 30 minutes apart.
  • the active ingredients may, and indeed usually will, be used in admixture with one or more pharmaceutically acceptable ingredients which may be selected, for example, from adjuvants, carriers, binders, lubricants, diluents, stabilising agents, buffering agents, emulsifying agents, viscosity-regulating agents, surfactants, preservatives, flavourings and colorants.
  • pharmaceutically acceptable ingredients which may be selected, for example, from adjuvants, carriers, binders, lubricants, diluents, stabilising agents, buffering agents, emulsifying agents, viscosity-regulating agents, surfactants, preservatives, flavourings and colorants.
  • the dosages administered will, of course, vary with the first and second active ingredients (A) and (B) employed, the mode of administration, the treatment desired and the disorder indicated. If the active ingredients are administered by inhalation, then the total daily dosage of first active ingredient (A) and second active ingredient (B) together is preferably in the range from 5 to 1500 ⁇ g, e.g. from 10 to 1450 ⁇ g or from 20 to 1400 ⁇ g.
  • the pharmaceutical composition, pharmaceutical product or kit according to the invention may be administered as divided doses from 1 to 4 times a day, and preferably once or twice a day.
  • the first and second active ingredients (A) and (B) may be administered topically (to the lung and/or airways) in the form of solutions, suspensions, aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions.
  • metered dose inhaler devices may be used to administer the active ingredient(s), dispersed in a suitable propellant and with or without additional excipients such as ethanol, surfactants, lubricants or stabilising agents.
  • Suitable propellants include hydrocarbon, chlorofluorocarbon and hydrofluoroalkane (e.g. heptafluoroalkane) propellants, or mixtures of any such propellants.
  • Especially preferred propellants are HFA-134a and HFA-227, each of which may be used alone or in combination with other propellants and/or surfactants and/or other excipients.
  • Nebulised aqueous suspensions or, preferably, solutions may also be employed, with or without a suitable pH and/or tonicity adjustment, either as a unit-dose or multi-dose formulations.
  • Dry powder inhalers may be used to administer the active ingredient(s), alone or in combination with a pharmaceutically-acceptable carrier, in the latter case either as a finely divided powder or as an ordered mixture.
  • the dry powder inhaler may be single dose or multi-dose and may utilise a dry powder or a powder-containing capsule.
  • Metered dose inhaler, nebuliser and dry powder inhaler devices are well known and a variety of such devices are available.
  • Tablets and gelatin capsules, which may be coated if desired, containing the active ingredient(s) may, for example, also include one or more diluents, carriers, binders, lubricants or stabilising agents.
  • Injectable solutions of the active ingredient(s) may also contain, for example, one or more preservatives, stabilising agents, viscosity-regulating agents, emulsifying agents or buffering agents.
  • the present invention further provides the use of a pharmaceutical composition, pharmaceutical product or kit according to the invention in the manufacture of a medicament for the treatment of an obstructive airways disease.
  • the present invention provides a method of treating, or reducing the risk of, an obstructive airways disease in a patient suffering from, or at risk of, the disease, which comprises administering to the patient a therapeutically effective amount of a pharmaceutical composition of the invention.
  • the present invention provides a method of treating, or reducing the risk of, an obstructive airways disease which comprises sequentially or separately administering (in any suitable order) to a patient suffering from, or at risk of, the disease (a) a (therapeutically effective) dose of a first active ingredient (A) being 4-hydroxy-7-[2- [2-[3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]- 1 ,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof; and (b) a (therapeutically effective) dose of a second active ingredient (B) being an anticholinergic muscarinic antagonist.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a pharmaceutical composition, pharmaceutical product or kit comprising a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]-1,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, and a second active ingredient (B) being an anticholinergic muscarinic antagonist, for use in the treatment of obstructive airways diseases.

Description

PHARMACEUTICAL COMPOSITIONS
The present invention relates to combinations of pharmaceutically active substances for use in the treatment of obstructive airways diseases.
In accordance with the present invention, there is therefore provided a pharmaceutical composition comprising, in admixture, a first active ingredient (A) being 4-hydroxy-7-[2- [2-[3-[2-phenylethoxy]propylsulphonyllethylamino]ethyl]- 1 ,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, and a second active ingredient (B) being an anticholinergic muscarinic antagonist.
The invention also provides a pharmaceutical product comprising, in combination, a preparation of a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]- propylsulphonyl]ethylamino]ethyl]-l,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, and a preparation of a second active ingredient (B) being an anticholinergic muscarinic antagonist for sequential or separate use in therapy.
In another aspect, the invention provides a kit comprising a preparation of a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]- ethylamino]ethyl]- 1 ,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, a preparation of a second active ingredient (B) being an anticholinergic muscarinic antagonist, and instructions for the sequential or separate administration of the preparations to a patient in need thereof.
The combination of active ingredients according to the invention is advantageous because it is beneficial in the treatment of obstructive airways diseases including chronic obstructive pulmonary disease (COPD); and asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness). 4-Hydroxy-7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]-l,3- benzothiazol-2(3H)-one and pharmaceutically acceptable salts thereof are described in WO 93/24473. The active ingredient (A) is most preferably 4-hydroxy-7-[2-[2-[3-[2- phenylethoxy]propylsulphonyl]ethylamino]ethyl]-l,3-benzothiazol-2(3H)-one hydrochloride.
Examples of the active ingredient (B) having anticholinergic activity include the muscarinic antagonists:
(endo, -.y«)-(±)-3-(3-Hydroxy- 1 -oxo-2-phenylpropoxy)-8-methyl-8-( 1 -methylethyl)-8- azoniabicyclo[3.2.1]octane bromide (ipratropium bromide);
(lα, 2β, 4β, 5a, 7β)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dirnethyl-3-oxa-9-
24 azoniatricyclo[3.3.1.0 ' Jnonane bromide (tiotropium bromide);
[7(S)-(lα, 2β, 4β, 5α, 7β)]-9-Ethyl-7-(3-hydroxy-l-oxo-2-phenylpropoxy)-9-methyl-
24 3-oxa-9-azoniatricyclo[3.3.1.0 ' ]nonane bromide (oxitropium bromide); and [3R-[3R*[S*(R*)]]]-α-(hydroxymethyl)-α-[2-(methylsulfinyl)ethyl]-benzeneacetic acid, l-azabicyclo[2.2.2]oct-3-yl ester (revatropate).
Methods of assaying for muscarinic receptor activity are described, for example, by N. Watson et al in Eur. J. Pharmacol, 285(2). 135-142 (1995).
The pharmaceutical composition of the invention may be prepared by mixing the first active ingredient (A) with the second active ingredient (B). Therefore, in another aspect of the present invention, there is provided a process for the preparation of a pharmaceutical composition which comprises mixing a first active ingredient (A) being 4-hydroxy-7-[2-[2- [3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]- 1 ,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, with a second active ingredient (B) being an anticholinergic muscarinic antagonist. The pharmaceutical composition of the invention will typically comprise a total amount of first active ingredient (A) and second active ingredient (B) in the range from 0.05 to 99 %w (per cent by weight), more preferably in the range from 0.10 to 70 %w, and even more preferably in the range from 0.10 to 50 %w, all percentages by weight being based on total composition.
The first and second active ingredients (A) and (B) may alternatively be administered sequentially or separately in any suitable order to treat obstructive airways diseases. By sequential is meant that the first and second active ingredients are administered one immediately after the other. They still have the desired effect if they are administered separately but less than about 4 hours apart, preferably less than about 2 hours apart, more preferably less than about 30 minutes apart.
The active ingredients may, and indeed usually will, be used in admixture with one or more pharmaceutically acceptable ingredients which may be selected, for example, from adjuvants, carriers, binders, lubricants, diluents, stabilising agents, buffering agents, emulsifying agents, viscosity-regulating agents, surfactants, preservatives, flavourings and colorants.
For the above-mentioned therapeutic uses the dosages administered will, of course, vary with the first and second active ingredients (A) and (B) employed, the mode of administration, the treatment desired and the disorder indicated. If the active ingredients are administered by inhalation, then the total daily dosage of first active ingredient (A) and second active ingredient (B) together is preferably in the range from 5 to 1500 μg, e.g. from 10 to 1450 μg or from 20 to 1400 μg.
The pharmaceutical composition, pharmaceutical product or kit according to the invention may be administered as divided doses from 1 to 4 times a day, and preferably once or twice a day.
The first and second active ingredients (A) and (B) may be administered topically (to the lung and/or airways) in the form of solutions, suspensions, aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions.
For example metered dose inhaler devices may be used to administer the active ingredient(s), dispersed in a suitable propellant and with or without additional excipients such as ethanol, surfactants, lubricants or stabilising agents.
Suitable propellants include hydrocarbon, chlorofluorocarbon and hydrofluoroalkane (e.g. heptafluoroalkane) propellants, or mixtures of any such propellants. Especially preferred propellants are HFA-134a and HFA-227, each of which may be used alone or in combination with other propellants and/or surfactants and/or other excipients.
Nebulised aqueous suspensions or, preferably, solutions may also be employed, with or without a suitable pH and/or tonicity adjustment, either as a unit-dose or multi-dose formulations.
Dry powder inhalers may be used to administer the active ingredient(s), alone or in combination with a pharmaceutically-acceptable carrier, in the latter case either as a finely divided powder or as an ordered mixture. The dry powder inhaler may be single dose or multi-dose and may utilise a dry powder or a powder-containing capsule.
Metered dose inhaler, nebuliser and dry powder inhaler devices are well known and a variety of such devices are available.
Tablets and gelatin capsules, which may be coated if desired, containing the active ingredient(s) may, for example, also include one or more diluents, carriers, binders, lubricants or stabilising agents. Injectable solutions of the active ingredient(s) may also contain, for example, one or more preservatives, stabilising agents, viscosity-regulating agents, emulsifying agents or buffering agents.
The present invention further provides the use of a pharmaceutical composition, pharmaceutical product or kit according to the invention in the manufacture of a medicament for the treatment of an obstructive airways disease.
Also, the present invention provides a method of treating, or reducing the risk of, an obstructive airways disease in a patient suffering from, or at risk of, the disease, which comprises administering to the patient a therapeutically effective amount of a pharmaceutical composition of the invention.
Still further, the present invention provides a method of treating, or reducing the risk of, an obstructive airways disease which comprises sequentially or separately administering (in any suitable order) to a patient suffering from, or at risk of, the disease (a) a (therapeutically effective) dose of a first active ingredient (A) being 4-hydroxy-7-[2- [2-[3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]- 1 ,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof; and (b) a (therapeutically effective) dose of a second active ingredient (B) being an anticholinergic muscarinic antagonist.

Claims

C L A I M S
1. A pharmaceutical composition comprising, in admixture, a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]- 1,3- benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, and a second active ingredient (B) being an anticholinergic muscarinic antagonist.
2. A composition according to claim 1, wherein, as first active ingredient (A), 4-hydroxy- 7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]-l,3-benzothiazol-2(3H)- one hydrochloride is used.
3. A composition according to claim 1 or claim 2, wherein, as second active ingredient (B), ipratropium bromide, tiotropium bromide, oxitropium bromide or revatropate is used.
4. A process for the preparation of a pharmaceutical composition as defined in claim 1 which comprises mixing a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2- phenylethoxy]propylsulphonyl]ethylamino]ethyl]- 1 ,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, with a second active ingredient (B) being an anticholinergic muscarinic antagonist.
5. Use of a pharmaceutical composition as claimed in any one of claims 1 to 3 in the manufacture of a medicament for the treatment of an obstructive airways disease.
6. Use according to claim 5 wherein the obstructive airways disease is chronic obstructive pulmonary disease or asthma.
7. A method of treating, or reducing the risk of, an obstructive airways disease in a patient suffering from, or at risk of, the disease, which comprises administering to the patient a therapeutically effective amount of a pharmaceutical composition as defined in any one of claims 1 to 3.
8. A method according to claim 7, wherein the obstructive airways disease is chronic obstructive pulmonary disease or asthma.
9. A pharmaceutical product comprising, in combination, a preparation of a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]- ethylamino]ethyl]-l,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, and a preparation of a second active ingredient (B) being an anticholinergic muscarinic antagonist for sequential or separate use in therapy.
10. A product according to claim 9, wherein, as first active ingredient (A), 4-hydroxy-7-[2- [2-[3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]-l,3-benzothiazol-2(3H)-one hydrochloride is used.
11. A product according to claim 9 or claim 10, wherein, as second active ingredient (B), ipratropium bromide, tiotropium bromide, oxitropium bromide or revatropate is used.
12. Use of a product as claimed in any one of claims 9 to 11 in the manufacture of a medicament for the treatment of an obstructive airways disease.
13. Use according to claim 12 wherein the obstructive airways disease is chronic obstructive pulmonary disease or asthma.
14. A kit comprising a preparation of a first active ingredient (A) being 4-hydroxy-7-[2-[2- [3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]- 1 ,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, a preparation of a second active ingredient (B) being an anticholinergic muscarinic antagonist, and instructions for the sequential or separate administration of the preparations to a patient in need thereof.
15. A kit according to claim 14, wherein, as first active ingredient (A), 4-hydroxy-7-[2-[2- [3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]-l,3-benzothiazol-2(3H)-one hydrochloride is used.
16. A kit according to claim 14 or claim 15, wherein, as second active ingredient (B), ipratropium bromide, tiotropium bromide, oxitropium bromide or revatropate is used.
17. A method of treating, or reducing the risk of, an obstructive airways disease which comprises sequentially or separately administering to a patient suffering from, or at risk of, the disease
(a) a dose of a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]- propylsulphonyl]ethylamino]ethyl]-l,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof; and (b) a dose of a second active ingredient (B) being an anticholinergic muscarinic antagonist.
PCT/GB2000/003118 1999-08-18 2000-08-14 Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist WO2001012167A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64604/00A AU6460400A (en) 1999-08-18 2000-08-14 Pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902935A SE9902935D0 (en) 1999-08-18 1999-08-18 Pharmaceutical compositions
SE9902935-7 1999-08-18

Publications (2)

Publication Number Publication Date
WO2001012167A2 true WO2001012167A2 (en) 2001-02-22
WO2001012167A3 WO2001012167A3 (en) 2001-09-20

Family

ID=20416693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003118 WO2001012167A2 (en) 1999-08-18 2000-08-14 Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist

Country Status (3)

Country Link
AU (1) AU6460400A (en)
SE (1) SE9902935D0 (en)
WO (1) WO2001012167A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049624A2 (en) * 2000-12-20 2002-06-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists
WO2002072095A2 (en) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium salts for treating inflammatory diseases
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2008096126A1 (en) * 2007-02-07 2008-08-14 Argenta Discovery Ltd Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist
US7700782B2 (en) 2006-12-20 2010-04-20 Astrazeneca Ab Compounds 569
US7709511B2 (en) 2005-08-09 2010-05-04 Astrazeneca Ab Benzothiazolone derivatives
US7951954B2 (en) 2006-03-14 2011-05-31 Astrazeneca Ab Bezothiazol derivatives as Beta2 adrenoreceptor agonists
US8017602B2 (en) 2008-06-18 2011-09-13 Astrazeneca Ab N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy
US8058294B2 (en) 2007-02-08 2011-11-15 Astrazeneca Ab Pharmaceutical salts of N-[2-(diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-napthyl)ethoxy]propanamide
US9687478B2 (en) 1999-07-14 2017-06-27 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024473A1 (en) * 1992-05-27 1993-12-09 Fisons Plc 7-(2-aminoethyl)-benzothiazolones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024473A1 (en) * 1992-05-27 1993-12-09 Fisons Plc 7-(2-aminoethyl)-benzothiazolones

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARNES P.J.: "New therapies for chronic obstructive pulmonary disease." THORAX, (1998) 53/2 (137-147). , XP000986442 *
CHAPMAN K R: "An international perspective on anticholinergic therapy." AMERICAN JOURNAL OF MEDICINE, (1996 JAN 29) 100 (1A) 2S-4S. REF: 19 , XP000986461 *
IKEDA A. ET AL: "Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease." DRUGS AND AGING, (1998) 12/2 (129-137). , XP000986468 *
LURIE A. ET AL: "Long-term management of reversible obstructive airways disease in adults." LUNG, (1990) 168/SUPPL. (154-167). , XP000986437 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588895B2 (en) 1999-07-14 2020-03-17 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9687478B2 (en) 1999-07-14 2017-06-27 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10034867B2 (en) 1999-07-14 2018-07-31 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
WO2002049624A3 (en) * 2000-12-20 2002-09-19 Boehringer Ingelheim Pharma Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists
WO2002049624A2 (en) * 2000-12-20 2002-06-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists
EP1690539A2 (en) * 2001-03-13 2006-08-16 Boehringer Ingelheim Pharma GmbH & Co. KG Salts of tiotropium for treating inflammatory disorders
EP1690539A3 (en) * 2001-03-13 2006-08-30 Boehringer Ingelheim Pharma GmbH & Co. KG Salts of tiotropium for treating inflammatory disorders
US7994188B2 (en) 2001-03-13 2011-08-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Compounds for treating inflammatory diseases
WO2002072095A3 (en) * 2001-03-13 2003-11-27 Boehringer Ingelheim Pharma Tiotropium salts for treating inflammatory diseases
WO2002072095A2 (en) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium salts for treating inflammatory diseases
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7838535B2 (en) 2003-11-21 2010-11-23 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7842704B2 (en) 2003-11-21 2010-11-30 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US8247564B2 (en) 2003-11-21 2012-08-21 Theravance, Inc. Compounds having BETA2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7709511B2 (en) 2005-08-09 2010-05-04 Astrazeneca Ab Benzothiazolone derivatives
US7951954B2 (en) 2006-03-14 2011-05-31 Astrazeneca Ab Bezothiazol derivatives as Beta2 adrenoreceptor agonists
US7700782B2 (en) 2006-12-20 2010-04-20 Astrazeneca Ab Compounds 569
AU2008212649B2 (en) * 2007-02-07 2011-05-19 Astrazeneca Ab Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist
CN101678005B (en) * 2007-02-07 2012-10-31 阿金塔探索有限公司 Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist
WO2008096126A1 (en) * 2007-02-07 2008-08-14 Argenta Discovery Ltd Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist
US8058294B2 (en) 2007-02-08 2011-11-15 Astrazeneca Ab Pharmaceutical salts of N-[2-(diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-napthyl)ethoxy]propanamide
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
US11000517B2 (en) 2008-03-13 2021-05-11 Almirall, S.A. Dosage and formulation
US8017602B2 (en) 2008-06-18 2011-09-13 Astrazeneca Ab N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients

Also Published As

Publication number Publication date
SE9902935D0 (en) 1999-08-18
WO2001012167A3 (en) 2001-09-20
AU6460400A (en) 2001-03-13

Similar Documents

Publication Publication Date Title
EP1158970B1 (en) Combinations of formoterol and a tiotropium salt
AU2004216472B2 (en) Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
US20080020048A1 (en) Treatment of Respiratory Disease
US20070243260A1 (en) Treatment of Childhood Asthma
PL200923B1 (en) SYNERGISTIC COMBINATION OF PDE INHIBITORS AND ß₂ ADRENOCEPTOR AGONIST
JP2004538241A (en) Combination drug containing tiotropium and fluticasone propionate
WO2001012167A2 (en) Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist
ZA200503308B (en) New synergistic combination comprising roflumilast and formoterol
US20060147382A1 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
US20060189642A1 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
WO2002028368A1 (en) New combination for the treatment of asthma
JP2007530616A (en) Pharmaceutical composition based on an anticholinergic agent and a CCR2 receptor antagonist
WO2001012192A2 (en) Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil
WO2005013992A1 (en) Medicaments for inhalation comprising betamimetics and an anticholinergic agent
US20060199865A1 (en) Synergistic combination comprising roflumilast and (r,r) - formoterol
WO2004084894A1 (en) Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases
EP1594540A1 (en) New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies
EP1718304A1 (en) Pharmaceutical compositions based on anticholinergics and pegsunercept

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09674084

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP